NYSEAMERICAN:PFNX - Pfenex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.02 -0.01 (-0.20 %)
(As of 09/20/2018 02:43 PM ET)
Previous Close$5.03
Today's Range$5.00 - $5.28
52-Week Range$2.07 - $8.42
Volume8,569 shs
Average Volume169,864 shs
Market Capitalization$106.11 million
P/E RatioN/A
Dividend YieldN/A
Beta3.6
Pfenex logoPfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. The company's lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that are in Phase I study. It develops PF529, a biosimilar candidate to Neulasta; PF530, a biosimilar candidate to Betaseron; and hematology/oncology products, including PF743 and PF745. The company has collaboration agreement with Jazz Pharmaceuticals Ireland Limited and Hospira, Inc., as well as a contract agreement with The National Institute of Allergy and Infectious Diseases. Pfenex Inc. is headquartered in San Diego, California.

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:PFNX
CUSIPN/A
Phone+1-858-3524400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-175.52%
Return on Equity-63.57%
Return on Assets-46.31%

Miscellaneous

EmployeesN/A
Outstanding Shares31,420,000
Market Cap$106.11 million

Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) posted its earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.05. The biotechnology company had revenue of $4.19 million for the quarter, compared to analyst estimates of $5.55 million. Pfenex had a negative return on equity of 63.57% and a negative net margin of 175.52%. View Pfenex's Earnings History.

When is Pfenex's next earnings date?

Pfenex is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Pfenex.

What price target have analysts set for PFNX?

3 Wall Street analysts have issued twelve-month price objectives for Pfenex's stock. Their predictions range from $8.00 to $8.00. On average, they anticipate Pfenex's stock price to reach $8.00 in the next year. This suggests a possible upside of 60.0% from the stock's current price. View Analyst Price Targets for Pfenex.

What is the consensus analysts' recommendation for Pfenex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pfenex.

Are investors shorting Pfenex?

Pfenex saw a drop in short interest during the month of August. As of August 31st, there was short interest totalling 667,417 shares, a drop of 10.4% from the August 15th total of 744,975 shares. Based on an average daily volume of 141,351 shares, the days-to-cover ratio is currently 4.7 days. Currently, 2.2% of the company's stock are sold short. View Pfenex's Current Options Chain.

Who are some of Pfenex's key competitors?

Who are Pfenex's key executives?

Pfenex's management team includes the folowing people:
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 46)
  • Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 60)
  • Mr. Patrick K. Lucy, Chief Bus. Officer (Age 50)
  • Dr. Hubert C. Chen, Advisor (Age 49)
  • Ms. Susan A. Knudson, Chief Financial Officer (Age 54)

Has Pfenex been receiving favorable news coverage?

News coverage about PFNX stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Pfenex earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Pfenex.

Who are Pfenex's major shareholders?

Pfenex's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.58%), Renaissance Technologies LLC (4.31%), Sanders Morris Harris LLC (3.72%), Dimensional Fund Advisors LP (2.25%), Russell Investments Group Ltd. (1.81%) and C WorldWide Group Holding A S (1.54%). Company insiders that own Pfenex stock include Evert B Schimmelpennink, Jason Grenfell-Gardner, Patricia Lady, Patrick K Lucy, Phillip M Schneider, Robin Campbell and Signet Healthcare Partners Acc. View Institutional Ownership Trends for Pfenex.

Which major investors are selling Pfenex stock?

PFNX stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Renaissance Technologies LLC and Commonwealth Equity Services LLC. View Insider Buying and Selling for Pfenex.

Which major investors are buying Pfenex stock?

PFNX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., Victory Capital Management Inc., Northern Trust Corp, Sio Capital Management LLC, C WorldWide Group Holding A S, Strs Ohio and Alambic Investment Management L.P.. Company insiders that have bought Pfenex stock in the last two years include Evert B Schimmelpennink, Jason Grenfell-Gardner, Phillip M Schneider and Robin Campbell. View Insider Buying and Selling for Pfenex.

How do I buy shares of Pfenex?

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfenex's stock price today?

One share of PFNX stock can currently be purchased for approximately $5.00.

How big of a company is Pfenex?

Pfenex has a market capitalization of $106.11 million.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.


MarketBeat Community Rating for Pfenex (NYSEAMERICAN PFNX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  150 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  273
MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe PFNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2018 by MarketBeat.com Staff

Featured Article: Relative Strength Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel